We’re proud to share our results for 2025
Click here for the Online reportMeet us at DCAT week
23-26 March 2026, New York city, Benjamin Suite 2601
Schedule a meeting with our teamCreating the future in peptides
We lead innovation in peptide API’s to the benefit of millions of patients
Contact usMarket leader in peptide API manufacturing and services
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) supporting pharmaceutical and biotech companies in the development and manufacturing of proprietary and generic active pharmaceutical ingredients (API).
Ad hoc announcements pursuant to Art. 53 LR
PolyPeptide delivers strong revenue growth and marked improvement in profitability
12 Mar 2026 - Baar, 12 March 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its annual results for 2025 […]
Read moreAd hoc announcements pursuant to Art. 53 LR
PolyPeptide successfully closes financial year 2025 with strong revenue growth and marked improvement in profitability
19 Jan 2026 - Baar, 19 January 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful closing of its […]
Read more